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Abstract 
Acute multifocal placoid pigment epitheliopathy (AMPPE) is an autoimmune chorioretinal 
disease that can be complicated by neurological involvement. There is limited information 
on this potentially treatable condition in the neurological literature. The objective of this 
patient series is to describe the neurological complications of AMPPE. We retrospectively 
identified patients with neurological complications of AMPPE seen at Auckland Hospital 
between 2008 and 2013 and summarised cases in the literature between 1976 and 2013. 
We identified five patients with neurological complications of AMPPE at Auckland Hospital 
and 47 reported patients. These patients demonstrated a spectrum of neurological 
involvement including isolated headache, stroke or transient ischaemic attack, seizures, 
venous sinus thrombosis, optic neuritis, sensorineural hearing loss and peripheral 
vestibular disorder. We propose criteria to define AMPPE with neurological complications. A 
cerebrospinal fluid (CSF) lymphocytosis in a patient with isolated headache may predict the 
development of cerebrovascular complications of AMPPE. Patients with cerebrovascular 
complications of AMPPE have a poor prognosis with high rates of death and neurological 
disability among survivors. Predictors of poor outcome in those who develop neurological 
complications of AMPPE are a relapsing course, generalised seizures and multifocal 
infarction on MRI. All patients with neurological complications of AMPPE, including 
headache alone, should be investigated with an MRI brain and CSF examination. Patients 
with focal neurological symptoms should receive intravenous (IV) methylprednisolone 
followed by a tapering course of oral steroids for at least 3 months. Patients with AMPPE 
and an isolated headache with a CSF pleocytosis should be treated with oral steroids  
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1. Introduction 
Acute multifocal placoid pigment epitheliopathy (AMPPE) is an uncommon inflammatory 
chorioretinal disorder [1] and [2]. AMPPE presents in young adults with the acute onset of 
photopsias and painless visual loss that is frequently bilateral. Characteristic retinal 
changes are creamy lesions that evolve over several weeks leaving retinal pigmentary 
changes. On fluorescein angiography, acutely these areas demonstrate early 
hypofluorescence and late hyperfluorescence consistent with impaired choroidal blood flow 
thought to be due to an inflammatory choriocapillaritis [2]. It remains unclear whether the 
characteristic retinal lesions are exudative or ischaemic in nature. The course is usually 
self-limiting with recovery of vision, although there may be residual retinal scarring. The 
visual prognosis is related to the degree of foveal involvement. The cause of AMPPE is 
uncertain, but several lines of evidence suggest that it is immune-mediated: association 
with other ocular and systemic inflammatory diseases, post-infectious and post-vaccination 
cases and the association with certain HLA types [2]. 
 
Patients with AMPPE can develop neurological complications but usually present with 
retinal disease before headache or focal neurological deficits develop. Imaging studies 
suggest the cause is cerebral vasculitis and this has been confirmed in three pathological 
cases showing granulomatous inflammation in the large, medium and small vessels in the 
brain and meninges [3], [4], [5] and [6]. 
 
Articles on AMPPE are rarely published in the neurological literature. The objective of this 
patient series is to describe the neurological complications of AMPPE so as to facilitate 
early recognition of this disorder and to summarise the clinical and radiological 
characteristics of neurological complications of AMPPE from the literature. 
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2. Methods 
We report five patients with AMPPE and neurological complications presenting to our 
institution and collected retrospectively between 2008 and 2013. Patients were included if 
they had AMPPE confirmed ophthalmologically and experienced neurological symptoms 
which included headache, focal neurological deficit, seizure or reduced level of 
consciousness. The findings of 47 published patients are combined with our five patients to 
examine the spectrum of neurological complications of AMPPE. To obtain the published 
cases of AMPPE, we performed an online medline search of the English literature. We used 
the search terms “AMPPE” and “APMPPE” as key words which identified 79 publications. 
We included all cases of AMPPE with neurological involvement including headache. 
Excluded were cases with isolated ocular disease. We analysed the clinical features of the 
combined series of patients to identify risk factors for poor outcome, defined as residual 
neurological deficit or death. Missing data points were omitted from the analysis. Follow-up 
data was collected from the most recently available clinic letter with a range of one to ten 
months following initial presentation, or as detailed in the published case reports. 
 
3. Patient reports 
3.1. Patient 1 
 
A previously well 26-year-old man presented to an ophthalmologist with headache and 
photopsia. Visual acuity was 20/50 bilaterally. The optic discs were normal and mild 
swelling was identified at the macula. He was diagnosed with central serous 
chorioretinopathy. Two days later he awoke with worsening headache and visual 
disturbance, difficulty with language and right arm weakness. A neurological examination 
showed an expressive dysphasia, right homonymous hemianopia and mild right 
Brownlee 5 
 
hemiparesis. MRI, including diffusion-weighted imaging (DWI) of the brain was normal and 
a lumbar puncture showed a normal opening pressure at 190 mm H2O, a lymphocytic 
meningitis (white cell count 61 × 106/L [normal range ⩽5 × 106/L]: 75% lymphocytes 
[normal range 60–80%], protein 92 mg/dl [normal range 0.15–0.45 mg/dl] and glucose 61.2 
mg/dl [normal range 2.8–4.4 mg/dl]). A further ophthalmology opinion was arranged. He 
was noted to have subretinal fluid over the maculae, ill-defined choroidal lesions in both 
eyes and early pigmentary changes. A fluorescein angiogram showed early 
hypofluorescence followed by later hyperfluorescence consistent with delayed choroidal 
filling (Fig. 1). He was treated with 1 g intravenous (IV) methylprednisolone for five days 
followed by a tapering dose of oral prednisone over two weeks. The patient’s expressive 
dysphasia, hemianopia and hemiparesis began to improve prior to starting corticosteroids 
and resolved within 24 hours. At follow up four weeks later his visual acuity had improved to 
6/6 bilaterally and he reported no further headaches. 
 
3.2. Patient 2 
 
A previously well 38-year-old man presented to an ophthalmologist with a two week history 
of headache, malaise and visual blurring. The visual acuity was 20/40 in the right eye and 
6/6 in the left eye. There were patchy retinal changes around the macula in the right eye. 
These changes were seen in the area of the optic disc and more peripherally in the left eye 
(Fig. 2). There was no visual field defect and the rest of the neurological examination was 
normal. MRI showed a small acute infarct in the right parietal lobe. MR angiography was 
normal. The patient was diagnosed with AMPPE with neurological complications and he 
was started on prednisone 60 mg/day. Four weeks later, while receiving prednisone 30 
mg/day his headache recurred, and he developed acute vertigo, nausea, unsteady gait and 
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worsening retro-orbital headaches. On examination he had left-beating nystagmus 
exacerbated by gaze to the left and a positive head thrust test to the right. He was unsteady 
walking but there were no focal signs in the limbs. Repeat MRI showed an old infarct in the 
right parietal lobe without any new lesion. CSF examination showed a normal opening 
pressure with a white cell count of 41 × 106/L: 82% lymphocytes, protein 55 mg/dl and 
normal glucose. He was diagnosed with a probable peripheral vestibular disorder although 
a small brainstem infarct could not be excluded. He was treated with one dose of 500 mg IV 
methylprednisolone, 3 days of 500 mg oral methylprednisolone and then a slowly reducing 
dose of methylprednisolone followed by oral prednisone. His symptoms slowly improved 
with persistent mild vertigo at 3 months, He remains on 20 mg/day of prednisone with a 
plan to continue a slow taper. The headache resolved promptly with IV methylprednisolone 
and has not recurred. 
 
3.3. Patient 3 
 
A 33-year-old woman presented with photophobia and visual loss in the right eye. Four 
days after the onset of symptoms she developed a frontal headache that slowly increased 
in intensity. Ophthalmological assessment showed visual acuity of counting fingers only 
with the right eye and 20/16 on the left. Fundoscopy showed multiple coalescing faint white 
subretinal opacities at the macula of the right eye. The left optic disc was normal. There 
was a mild relative afferent pupillary defect in the right eye. Fundoscopic examination of the 
left eye was normal. She was commenced on 80 mg of oral prednisone. She did not 
develop any further neurological symptoms and the remainder of the neurological 
examination was normal. MRI with angiography was normal and a CSF examination was 
normal including an opening pressure at 190 mm H2O. The dose of prednisone was 
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reduced over five weeks. Five months after symptom onset she was free of headaches. 
Visual acuity had improved to 20/100 in right eye and 20/16 in the left. 
 
3.4. Patient 4 
 
A 41-year-old man developed a headache with visual blurring and photopsia. A few days 
after the onset of symptoms he had three episodes of transient expressive dysphasia each 
lasting for several minutes over the course of a single day. Sumatriptan was prescribed for 
the headache, but made the headache worse. He then developed scotomas in his vision 
and visual distortion and presented to the ophthalmology service. Visual acuity was 6/6 in 
both eyes. There were creamy pigmented lesions classical for AMPPE at both posterior 
poles. He was started on prednisone 80 mg/day with improvement in the headaches. A 
neurological examination was normal. MRI was normal and a CSF showed white cell count 
30 × 106/L: 93% lymphocytes with protein 39 mg/dl. An opening pressure was not recorded 
as the CSF was obtained in the seated position. The dose of prednisone was slowly 
reduced. Three months after symptom onset, while taking prednisone 40 mg/day, the 
patient had a recurrence of headaches and developed migratory left hemisensory 
paraesthesiae and numbness with mild left hand weakness. The focal symptoms resolved 
over 3 hours. A neurological examination and repeat MRI after symptom resolution were 
both normal. The patient was treated with a single dose of 500 mg IV methylprednisolone 
followed by 200 mg of oral methylprednisolone for 5 days and 100 mg for 3 days with a 
subsequent slow oral prednisone taper over 4 months. The patient’s headaches resolved 
and he experienced no further neurological symptoms. 
3.5. Patient 5 
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A 27 year old presented to an ophthalmologist with a history of headache followed 3 days 
later by visual impairment with photopsia. His visual acuity was 20/20 bilaterally. Two 
placoid lesions were identified in the posterior pole of the left eye. He was diagnosed with 
AMPPE. Three days later he noted deterioration in his vision. Visual acuity at this time was 
20/32 in the left eye and 20/16 in the right. He was started on 80 mg of prednisone. A 
neurological examination was normal as was MRI of the brain including MR angiography, 
MR venography was not performed. A CSF examination showed a normal opening 
pressure of 186 mm H2O, 68 × 106/L white cells: 81% lymphocytes, normal protein and 
glucose. The headache and visual symptoms slowly resolved. Two months after the onset 
of symptoms on a dose of 20 mg of prednisone his headaches recurred. The prednisone 
was increased to 40 mg with resolution of the headache and the prednisone was reduced 
by 5 mg per week until discontinued with no recurrence of the headache. 
 
4. Review of the literature 
 
A review of the published literature in the English language between 1976 and 2013 and 
including our five patients identified 52 patients in whom AMPPE was associated with 
neurological symptoms [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], 
[19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29] and [30]. The mean age was 28.8 
years (range 11–54 years) which is similar to that reported in a large series of patients with 
uncomplicated AMPPE [2] and [31]. Males accounted for more than two thirds of patients 
with neurological symptoms suggesting male gender may be a risk factor for neurological 
complications of AMPPE. No gender difference has been identified from case series of 
ocular AMPPE [28] and [32]. 
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4.1. Neurological complications of AMPPE 
The proportion of patients with ocular AMPPE that develop neurological complications has 
not been reported. One retrospective database review of all acute AMPPE patients 
presenting to one centre found 11/18 (61%) patients had neurological symptoms and one 
had a stroke [28]. Data missing from published case reports was not counted. In the 
majority of cases the visual symptoms preceded neurological complications. 
 
Transient ischaemic attacks (TIA) or strokes occurred in 31/52 (60%) patients with 
neurological complications of AMPPE. Twenty two of 31 (71%) of patients with a TIA or 
stroke had evidence of an ischaemic lesion on CT scan or MRI. In the nine patients without 
a lesion, 5/9 had not had an MRI of the brain. The most common clinical presentation was 
that of a hemiparaesis, seen in 15/31 (48%), followed by a dysphasia or aphasia in 9/31 
(29%). Other complications were a hemisensory disturbance in 6/31 (19%) or hemianopia 
in 5/31 (16%). Dysarthria in 4/31 (13%), ataxia in 3/31 (10%) and diplopia in 1/31 (3%) 
occurred less commonly. 
 
The timing of vascular events in relation to the onset of the ocular symptoms was reported 
in 26/31 (84%) patients. In 17 of these 26 (65%) patients, the events occurred less than 4 
weeks after the onset of visual symptoms. There are no reported cases in which ischaemic 
events occurred prior to visual symptoms and only 1/52 (2%) patients in which headache 
preceded the visual symptoms. Late presentations occurred in three patients at 6 and 12 
months and 5 years after the onset of ocular symptoms. The mean time to onset of 
neurological symptoms from eye symptoms was 19 weeks. The anterior circulation was 
involved in 12/31 (39%), the posterior circulation in 9/31 (29%) and in 10/31 (32%) patients 
cerebral infarcts occurred in multiple vascular territories. MRI was consistent with ischaemic 
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strokes in the majority of patients but in one case series, one patient had an intracerebral 
haemorrhage complicating superior sagittal sinus thrombosis [17]. Seventy percent of 
patients with cerebrovascular complications were male. The majority of patients 23/31 
(74%) who developed cerebrovascular complications reported a headache. All patients who 
developed stroke or TIA, in whom a CSF result was reported had increased CSF 
lymphocytes, although one such patient had an initially normal result [28]. 
 
Cerebrovascular complications in patients with AMPPE are thought to be secondary to 
cerebral vasculitis as this has been demonstrated pathologically in three published cases, 
included in this case series, with autopsy findings. A granulomatous vasculitis affecting the 
left middle cerebral artery was seen in one patient and in the meningeal arteries in two [4], 
[5] and [6]. Perivascular cuffing was also evident in the small intracerebral arteries [4]. Of 
the patients presenting with cerebrovascular complications 11/31 (35%) had evidence of a 
possible vasculitis on MR angiography or catheter angiography. Formal catheter 
angiography has shown evidence of small vessel disease with findings of diffuse narrowing, 
segmental narrowing and in some cases a typical beading appearance [3], [10], [12], [14], 
[19], [23] and [29]. 
 
Isolated headache, defined as headache without other neurological symptoms, with normal 
brain imaging and CSF examination, occurred in 11/52 (21%) patients. The features of 
headache complicating AMPPE are poorly characterised in published case histories but 
where described the headaches were severe [5], [6], [17], [22] and [23], persistent [17], [26] 
and [27], localised [5] or diffuse [6]. Meningitic symptoms were described in the minority 
with only 4/52 (8%) patients experiencing either neck stiffness [9] and [10], fever [18] or 
photophobia [22]. 
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Seizures occurred in four patients, one of unspecified type. One patient had focal seizures 
associated with a new DWI lesion on MRI imaging [26]. Two other patients had generalised 
seizures; both patients died. At autopsy ischaemic change was found in large areas of the 
cerebral cortex in both patients [4] and [5]. 
 
4.2. Prognosis 
The prognosis of patients with AMPPE with neurological involvement is variable. At least 
short term follow up information is available for 40/52 (77%) patients. 25/40 (62%) made a 
full recovery, 10/40 (25%) had residual neurological disability, 5/40 died (13%). If the 
analysis is limited to patients who presented with a TIA or stroke then the prognosis is 
relatively poor with half of patients having a residual neurological disability or dying. The 
two patients who experienced generalised seizures died [4] and [5]. There was no 
statistically significant difference in outcome based on the age of the patient at presentation 
or severity of the ocular disease as measured by visual acuity. 
 
In this review, 23/31 (74%) of patients with cerebrovascular complications had the results of 
MRI reported. Multifocal infarction on MRI was seen in 10/31 (32%) patients. Of these, 4/10 
(40%) patients died. Multifocal infarction on imaging was a risk factor for poor outcome. (p < 
0.004). There was no statistically significant difference in outcome based on whether the 
initial MRI result was normal although the numbers are low. Normal MRI was seen in 5 of 
23 (22%) patients with cerebrovascular complications of AMPPE, four of whom had no 
residual deficit. Caution is needed when using normal imaging at presentation to 
prognosticate as one patient with initial normal imaging went on to have a fulminant course 
and died with multifocal brain involvement. 
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Patients with a relapsing course had a worse outcome compared with those with a 
monophasic course (p = 0.005). 11/39 (26%) patients had a relapsing course, of whom 6/11 
(55%) had a residual neurological deficit. 29/35 (85%) patients with a monophasic 
neurological presentation made a full recovery, none died. Five patients presented with a 
rapidly progressive course defined as dying within 4 weeks of neurological presentation [4], 
[5], [6], [13] and [27]. 
 
The number of CSF white cells did not predict whether patients made a full recovery or had 
residual deficit or died (p = 0.2). However, only 2/5 (40%) of the patients who died had the 
results of CSF analysis recorded. 
 
4.3. Treatment 
 
There is information on medical management in 40/52 (77%) of the cases. The majority, 
36/40 (90%), were treated with steroids or other immunosuppressive agents. 8/40 (20%) 
with IV steroids, 5/40 (13%) with azathioprine, 4/40 (10%) with cyclophosphamide and one 
patient received IV methylprednisolone without oral steroid in combination with 
mitoxantrone. There was a large variation in the duration of therapy with patients receiving 
weeks to years of immunosuppressant therapy. Immunosuppressant agents were added to 
steroids for a clinical deterioration with the development of neurological complications in 
6/10 patients (60%). In 4/10 (40%) patients additional immunosuppression was used for 
steroid sparing. 
5. Discussion 
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AMPPE is an inflammatory chorioretinal disorder complicated by neurological involvement. 
Patients with AMPPE may present to neurologists with headache or focal neurological 
symptoms and a history of reduced visual acuity or photopsia. In an appropriate clinical 
setting a careful slit-lamp examination looking for presence of intraocular inflammation and 
for the characteristic retinal lesions is the most important part of reaching the ocular 
diagnosis. Investigations such as fluorescein angiography and ocular coherence 
topography will further support this diagnosis. 
 
Patients with cerebrovascular complications of AMPEE have a relatively poor prognosis 
with high rates of death and neurological disability among survivors. Imaging studies 
suggest the cause is a cerebral vasculitis and this has been confirmed in three pathological 
cases showing granulomatous inflammation of vessels. Given the proposed immune 
mechanisms of AMPPE and the possibility of an unfavourable outcome, early consideration 
should be given to the use of immunosuppression. 
 
This case series and review of the literature has summarised the neurological complications 
of AMPPE. These range from isolated headache without evidence of meningeal 
inflammation, to headache with evidence of meningeal inflammation, to stroke or TIA. In the 
majority, the onset of neurological symptoms is preceded by symptoms of retinal disease. 
Based on the published cases we propose the criteria in Table 1 for the diagnosis of 
AMPPE with neurological complications. 
 
5.1. Predictors of developing cerebrovascular complications of AMPPE 
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The ability to identify patients at risk of progressing from isolated eye disease to central 
nervous system involvement would be helpful to guide treatment. There is uncertainty about 
how aggressively patients should be treated with immunosuppression and for what 
duration. 
 
The majority of patients with cerebrovascular complications of AMPPE had a CSF 
pleocytosis. In those patients with AMPPE presenting with an isolated headache, the 
presence of a CSF pleocytosis may indicate impending cerebrovascular ischaemia. 
5.2. Predictors of poor outcome in neurological AMPPE 
 
Several factors identified in this review appeared to be associated with a poor outcome. 
These are a relapsing or rapidly progressive clinical course, generalised seizures and 
multifocal neuroimaging findings. 
 
There are no randomised controlled trials to guide the treatment of neurological 
complications of AMPPE. Given the proposed immune mechanisms of AMPPE and the 
possibility of residual neurological deficits or death, early consideration should be given to 
starting immunosuppression. We suggest that all patients with AMPPE with neurological 
symptoms, including isolated headache, have an MRI and CSF examination. Those 
patients with focal neurological symptoms should be treated with a short course of 500 mg 
IV methylprednisolone followed by a tapering course of oral steroids for a period of at least 
3 months. Patients with AMPPE and an isolated headache, with either an abnormal MRI or 
CSF, should be treated with 1 mg/kg of oral prednisone tapering down over a period of 3 
months. 
 
Brownlee 15 
 
Patients presenting with a relapsing course, generalised seizures or multifocal 
abnormalities on brain imaging may require more protracted treatment. Patients who are 
already receiving corticosteroids when cerebrovascular complications develop may require 
more intensive immunosuppression with azathioprine, cyclophosphamide or mitoxantrone 
[16], [17], [23] and [24]. 
 
The published literature likely reflects a bias to more severe patient presentations and 
therefore the above results may not be generalisable to individual patients with neurological 
complications of AMPPE. The five patients from our site had relatively mild complications. 
The predictors we identified were from a collation of data from several sources and 
therefore statistical analysis to determine their significance may not be robust. There is a 
need for a prospective study of patients with AMPPE to document the incidence and 
spectrum of neurological complications and statistically confirm the predictive factors 
identified in this literature review. 
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Table 1. Proposed criteria for the diagnosis of AMPPE with neurological complications 
Ophthalmological evidence of AMPPE 
 
 
Multiple yellow-white subretinal lesions, typically bilateral 
Predilection for posterior pole 
Pigmentary change over lesions within days to months 
Variable degree of anterior chamber and vitreous activity (may be absent) 
Supported by characteristic findings on fluorescein and indocyanine green 
angiography  
And one or more of the following  
 
Headache  
Stroke or transient ischaemic attack  
CSF pleocytosis 
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